Bispecific Antibodies in the Treatment of Hematologic Malignancies.

Autor: Duell J; Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany., Lammers PE; Baptist Cancer Center, Memphis, Tennessee, USA., Djuretic I; Pfizer, Inc, South San Francisco, California, USA., Chunyk AG; Pfizer, Inc, La Jolla, California, USA., Alekar S; Pfizer, Inc, La Jolla, California, USA., Jacobs I; Pfizer, Inc, New York, New York, USA., Gill S; Blood and Marrow Transplantation Program, Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Oct; Vol. 106 (4), pp. 781-791. Date of Electronic Publication: 2019 Mar 29.
DOI: 10.1002/cpt.1396
Abstrakt: Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.
(© 2019 Pfizer Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: